P2B001: A Phase 3, Twelve-week, Multi-Center, Multinational, Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to its Individual Components in Subjects With Early

Grants and Contracts Details

StatusFinished
Effective start/end date3/12/18 → 1/18/22

Funding

  • Pharmaceutical Research Associates: $120,583.00